- Rocket Lab completed its 84th Electron launch — its 8th consecutive successful mission for Synspective — and extended that partnership to include 19 additional dedicated launches before 2028.
- The company signed a $190 million block-buy contract for 20 hypersonic test flights using its Haste vehicle under the U.S. Department of Defense’s MACH-TB 2.0 program, with the first flight expected within months.
- Q1 2026 revenue hit $200.35 million, up 63.4% year over year, beating estimates, with a record $2.2 billion backlog — yet RKLB shares are down roughly 13% in a single session amid sector-wide rotation.
RKLB YTD: -5% (pre-Monday session)
Rocket Lab’s RKLB stock has a new, concrete revenue anchor. The company signed a block-buy contract worth $190 million covering 20 hypersonic test flights with its Haste launch vehicle. The work falls under the Test Resource Management Center’s Multi-Service Advanced Capability Hypersonic Test Bed 2.0 program — a Department of Defense effort executed in partnership with Naval Surface Warfare Center Crane Division. Rocket Lab operates under Task Area 1, led by Kratos Defense, and will execute the 20 flights over four years. The first mission is expected within months of contract signing. That is not a vague pipeline entry. It is a funded, multi-year program with a defined cadence. Separately, Rocket Lab completed Electron mission 84 — its eighth consecutive successful launch for Japan-based Synspective — deploying a synthetic aperture radar Earth-imaging satellite. The company holds a 100% mission success rate across all Synspective flights. That partnership has now been extended to cover 19 additional dedicated launches, delivering the remainder of Synspective’s constellation to orbit before 2028. Two data points in one week: a defense contract with immediate execution timelines and a commercial partnership extension with nearly two dozen future launches attached. The backlog, already at $2.2 billion as of Q1, has fresh fuel.
RKLB stock dropped roughly 13% in Monday’s session, extending a 6% decline from Friday. The proximate cause is sector rotation triggered by a Blue Origin New Glenn hotfire failure at Cape Canaveral, which pulled capital out of launch-exposed names broadly. This is a sentiment-driven move, not a fundamentals-driven one. Rocket Lab beat Q1 estimates on both the top and bottom lines. Revenue came in at $200.35 million against a $189.65 million consensus. EPS matched estimates at -$0.07, improving from -$0.12 in the year-ago period. The company signed 31 new Electron and Haste contracts plus five dedicated Neutron missions in Q1 alone. Institutional ownership sits at 71.78%, with Capital World Investors holding over 16 million shares. Analyst consensus is Moderate Buy with an average price target of $98.88, though Needham recently set a $120 target and Stifel holds a Street-high $132. The stock traded above $147 as recently as late May. The gap between that level and Monday’s $124 handle is not explained by anything Rocket Lab did or failed to do operationally. The stock had a 366% year-over-year run entering this week. Profit-taking after that kind of move needs no fundamental justification. Insiders sold shares in late May under pre-arranged 10b5-1 plans — a scheduled event, not a signal — but the volume, roughly 485,000 shares over 90 days valued near $67 million, is worth tracking in context.
Rocket Lab delivered operationally this week on two fronts: a flawless commercial launch extending a perfect record with a key customer, and a $190 million defense contract with near-term execution. The Q1 print — 63% revenue growth, a record backlog, and margin expansion — remains intact. The stock’s Monday selloff reflects sector sentiment and post-rally de-risking, not a deterioration in Rocket Lab’s business. That said, RKLB carries a beta of 2.49 and a market cap above $63 billion on negative earnings, which means volatility is the price of admission here. The fundamentals are building. The multiple is doing its own thing.
The timing of the first MACH-TB 2.0 Haste flight and any update on Neutron’s debut timeline — these are the next hard catalysts that can either validate or stress-test the current valuation.
Disclaimer: This post is for informational purposes only and does not constitute investment advice. All investment decisions and their outcomes are solely the responsibility of the reader.
Sources: Stocktwits, MarketBeat, AOL Finance